Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

HCW Biologics Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/24/2023 8-K Other Events  Interactive Data
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Quarterly results
Docs: "HCW Biologics Reports Second Quarter 2023 Financial Results And Recent Business Highlights Miramar, FL – August 11, 2023 – HCW Biologics Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2023. “During the period ended June 30, 2023, we have made significant progress in crystalizing our understanding of the anti-cancer mechanism of action of HCW9218, especially in relation to how it complements immune checkpoint inhibitors . HCW9218 has a unique mechanism that we believe allows it to turn a ‘cold’ tumor into a ‘hot’ tum..."
08/10/2023 10-Q/A Quarterly Report for the period ended March 31, 2023 [amend]
06/15/2023 4 Winer Gary M (Director) has filed a Form 4 on HCW Biologics Inc.
Txns: Granted 12,500 options to buy @ $2.01, valued at $25.1k
06/15/2023 4 GARRETT SCOTT T (Director) has filed a Form 4 on HCW Biologics Inc.
Txns: Granted 12,500 options to buy @ $2.01, valued at $25.1k
06/15/2023 4 Greene Rick S. (Director) has filed a Form 4 on HCW Biologics Inc.
Txns: Granted 12,500 options to buy @ $2.01, valued at $25.1k
06/15/2023 4 Giles Lisa M. (Director) has filed a Form 4 on HCW Biologics Inc.
Txns: Granted 12,500 options to buy @ $2.01, valued at $25.1k
06/09/2023 4 Flowers Lee (SVP of Business Development) has filed a Form 4 on HCW Biologics Inc.
Txns: Bought 10,000 shares @ $2.1574, valued at $21.6k
Exercised 5,356 options to buy @ $0.14, valued at $749.8
06/09/2023 4 Byam Rebecca (CFO) has filed a Form 4 on HCW Biologics Inc.
Txns: Bought 20,000 shares @ $2.0643, valued at $41.3k
06/08/2023 4 Byam Rebecca (CFO) has filed a Form 4 on HCW Biologics Inc.
Txns: Bought 20,000 shares @ $2.0316, valued at $40.6k
Bought 4,696 shares @ $2.212, valued at $10.4k
06/07/2023 4 Byam Rebecca (CFO) has filed a Form 4 on HCW Biologics Inc.
Txns: Bought 20,000 shares @ $1.6672, valued at $33.3k
Bought 19,062 shares @ $1.8245, valued at $34.8k
06/02/2023 4 Wong Hing C (CEO) has filed a Form 4 on HCW Biologics Inc.
Txns: Bought 800 shares @ $1.6178, valued at $1.3k
Bought 800 shares @ $1.5353, valued at $1.2k
06/01/2023 4 Wong Hing C (CEO) has filed a Form 4 on HCW Biologics Inc.
Txns: Bought 3,000 shares @ $1.5527, valued at $4.7k
Bought 2,000 shares @ $1.546, valued at $3.1k
06/01/2023 4 Winer Gary M (Director) has filed a Form 4 on HCW Biologics Inc.
Txns: Bought 850 shares @ $1.5206, valued at $1.3k
Bought 500 shares @ $1.5, valued at $750
05/31/2023 4 Byam Rebecca (CFO) has filed a Form 4 on HCW Biologics Inc.
Txns: Bought 20,000 shares @ $1.6174, valued at $32.3k
Bought 20,000 shares @ $1.6598, valued at $33.2k
05/24/2023 4 Byam Rebecca (CFO) has filed a Form 4 on HCW Biologics Inc.
Txns: Bought 33,450 shares @ $1.526, valued at $51k
Bought 5,036 shares @ $1.5662, valued at $7.9k
Bought 20,000 shares @ $1.6075, valued at $32.2k
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights Miramar, FL – May 9, 2023 – HCW Biologics Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2023. “We measure our progress over the past year by the achievement of significant milestones: Initiating multiple clinical trials. Realizing the dream of establishing our own manufacturing facility. Publishing ground-breaking scientific papers,” stated Dr. Hing C. Wong, Founder and CEO of HCW Biologics. Dr. Wong continued, “Our primary pr..."
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/27/2023 8-K Quarterly results
03/28/2023 10-K Annual Report for the period ended December 31, 2022
03/28/2023 8-K Quarterly results
12/07/2022 8-K Other Events  Interactive Data
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/07/2022 8-K Quarterly results
Docs: "HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights Miramar, FL – November 7, 2022 – -- HCW Biologics Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2022. Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, stated, “We are pleased to report that during the third quarter we opened three clinical sites for our second clinical trial to evaluate HCW9218 in patients with advanced pancreatic cancer. HonorHealth Research Institute was the first clinical site to dose a patie..."
11/03/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/15/2022 4 Byam Rebecca (CFO) has filed a Form 4 on HCW Biologics Inc.
Txns: Bought 15,000 shares @ $2.5767, valued at $38.7k
09/14/2022 4 Byam Rebecca (CFO) has filed a Form 4 on HCW Biologics Inc.
Txns: Bought 15,000 shares @ $2.6509, valued at $39.8k
Bought 15,000 shares @ $2.5767, valued at $38.7k
09/12/2022 4 Wong Hing C (CEO) has filed a Form 4 on HCW Biologics Inc.
Txns: Bought 4,000 shares @ $2.67, valued at $10.7k
Bought 6,000 shares @ $2.7, valued at $16.2k
09/07/2022 4 Wong Hing C (CEO) has filed a Form 4 on HCW Biologics Inc.
Txns: Bought 4,000 shares @ $2.55, valued at $10.2k
Bought 6,000 shares @ $2.58, valued at $15.5k
09/01/2022 4 Byam Rebecca (CFO) has filed a Form 4 on HCW Biologics Inc.
Txns: Bought 7,200 shares @ $2.5474, valued at $18.3k
Bought 10,000 shares @ $2.5572, valued at $25.6k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy